Predicting Immunotherapy Response in Bladder Cancer
By Robert Dreicer, MD
PUBLISHED WEDNESDAY, DECEMBER 31, 1969
When it comes to predicting response to checkpoint inhibitors for patients with urothelial carcinoma, PD-L1 status may not be the most accurate factor, explained Robert Dreicer, MD, deputy director of UVA Cancer Center, director of solid tumor oncology within the division of hematology/oncology and is a professor of medicine and urology at the University of Virginia.
PD-L1 is not the most reliable predictor because there are many patients whose tumors are not PD-L1 positive who still respond to immunotherapy. More research in this field is still warranted.
You must log in to use this feature, please click here to login.